Theratechnologies (THTX) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" THTX shares.
View THTX analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12-month price objectives for Theratechnologies' shares. Their THTX share price forecasts range from $36.00 to $36.00. On average, they anticipate the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 1,543.8% from the stock's current price.
View analysts price targets for THTX or view top-rated stocks among Wall Street analysts.

Theratechnologies' stock was trading at $3.5312 on January 1st, 2023. Since then, THTX stock has decreased by 38.0% and is now trading at $2.19.
View the best growth stocks for 2023 here.

Theratechnologies saw a increase in short interest in August. As of August 31st, there was short interest totaling 83,500 shares, an increase of 126.9% from the August 15th total of 36,800 shares. Based on an average daily trading volume, of 204,300 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.4% of the company's shares are sold short.
View Theratechnologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023.
View our THTX earnings forecast.

Theratechnologies Inc. (NASDAQ:THTX) announced its quarterly earnings data on Wednesday, July, 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.16. The firm earned $17.55 million during the quarter.

Shares of Theratechnologies reverse split on the morning of Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Theratechnologies issued an update on its FY 2023 earnings guidance on Thursday, July, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $82.00 million-$87.00 million, compared to the consensus revenue estimate of $91.66 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX).

Theratechnologies trades on the NASDAQ under the ticker symbol "THTX."

Theratechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include National Bank of Canada FI (0.56%), Osaic Holdings Inc. (1.84%), Osaic Holdings Inc. (1.84%), Cibc World Market Inc. (1.73%), Bank of Montreal Can (0.31%) and Two Sigma Securities LLC (0.22%).

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of THTX stock can currently be purchased for approximately $2.19.

Theratechnologies (NASDAQ:THTX) has a market capitalization of $53.00 million and generates $80.06 million in revenue each year. The company earns $-47,240,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

The company employs 144 workers across the globe.

Theratechnologies' mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The official website for the company is www.theratech.com. The company can be reached via phone at (514) 336-7800, via email at communications@theratech.com, or via fax at 514-331-9691.